ViferaXS develops off-the-shelf peptide-based cancer immunotherapies that activate T cells against tumor antigens for patients with blood cancers and solid tumors.

Founders

• Prof. Hans-Georg Rammensee · Co-Founder and Immunologist
  He is a leading immunologist and cancer immunotherapy researcher at the University of Tübingen whose work covers MHC molecules, tumor-specific peptides and personalized cancer vaccines.
• Prof. Dr. Juliane Walz · Co-Founder and Immunologist / Oncologist
  She is a physician trained in hematology and oncology and is Head of Peptide-based Immunotherapy and Medical Director of the Clinical Cooperation Unit for Translational Immunology at University Hospital Tübingen.

Total raised

up to €12 million, including grant funding · as its sources put it, more than the rounds on record